Endocrinologists Discover Metformin can be used to Save Their Patients from COVI

Posted by Robert on March 16th, 2021

Recent studies have reported that people who suffer from diabetes, had a significantly reduced risk of death from COOVID-19 complications when they took the medication metformın. - This data was analyzed from a diverse patient population, where researchers compared two controlled groups of individuals and found that those who had been taking metformin (a drug designed for type 2 diabetes), were less likely to die of COVID-19 than those who were not taking metformin. The Frontiers in Ëndocrinology journal was the first to publısh these findings.

Statistics concerning diabetes and metformin After conducting nearly a year of research, scientists, and Healthcare professionals have found numerous similarities between those infected with COVID-19, most of which are listed below: Most people who tested positive for COVID-19, 70°% had hypertension, 61o had obesıty, and 40o had diabetes. - 11% of COVID-19 patients died, most of whom (93%) were over the age of 50. Being male and having hypertension were also contributing factors in having an increased risk of death from COVID-19. - 67% of COVID-19 related deaths, came from people who were diagnosed with diabetes. Indicating that this condition had a particularly significant effect on the risk of death. Researchers began to analyze different disparities and patterns within datasets, to figure out what were key independent risk factors for COVID-19 deaths. Age, sex, and diabetes Were considered the most telling datasets between individuals. Once it was discovered that people diagnosed with diabetes were among the most vulnerable to COVID-19, researchers focused on the science behind the matter. The results have so far proven to be groundbreakıng, as they found "that those who tested positive who were taking metformın- had an 11% rısk of dyıng. which was the same as that of the general populatıon. In comparıson, those with diabetes, not takıng metformın had a 24% risk of dying".

Researchers began to analyze different disparities and patterns withın datasets, to figure out what were key independent risk factors for COVID-19 deaths. Age, sex, and diabetes were considered the most telling datasets between individuals. Once it was discovered that people diagnosed with diabetes were among the most vulnerable to COVID-19, researchers focused on the science behind the matter. The results have so far proven to be groundbreaking, as they found "that those who tested positive who were taking metformin- had an 11o risk of dyıng, which was the same as that of the general populatıon. In comparıson, those with diabetes, not takıng metformın had a 24% risk of dying. Professor Anath Shalev, one of the researchers behind this study noted that the beneficial effect was not attracted by factors, such as race, age, obesity, sex, heart failure, or kidney failure. She would also go on to say, "Since similar results have now been obtained in different populations from around the world -includıng China, France, and an [UnitedHealth] analys1s-this suggests that the observed reduction in mortality risk associated with metformin use in subjects with type 2 diabetes and COVID-19 might be generalizable." Why metformin has these effects on diabetes patients, has still not been answered, however, one theory is the drug could be improving glycemic control or obesity.